Germany biotech gets second chance.
作者信息
Sheridan Cormac
出版信息
Nat Biotechnol. 2003 Dec;21(12):1414-5. doi: 10.1038/nbt1203-1414.
PMID:14647310
Abstract
摘要
相似文献
1
Germany biotech gets second chance.
Nat Biotechnol. 2003 Dec;21(12):1414-5. doi: 10.1038/nbt1203-1414.
2
Biotech parks proliferate, despite concerns over sustainability.
Nat Biotechnol. 2003 Nov;21(11):1259-60. doi: 10.1038/nbt900.
3
France to focus on a few biotech clusters.
Nat Biotechnol. 2004 Sep;22(9):1063-4. doi: 10.1038/nbt0904-1063.
4
Benefits of biotech clusters questioned.
Nat Biotechnol. 2003 Nov;21(11):1258-9. doi: 10.1038/nbt902.
5
Michigan's next wave of biopharmaceutical entrepreneurship.
Nat Biotechnol. 2003 Sep;21(9):1109-11. doi: 10.1038/nbt0903-1109.
6
More than the sum of their parts? Clustering is becoming more prevalent in the biosciences, despite concerns over the sustainability and economic effectiveness of science parks and hubs.
EMBO Rep. 2006 Feb;7(2):133-6. doi: 10.1038/sj.embor.7400633.
7
Increasing number of companies found ineligible for SBIR funding.
Nat Biotechnol. 2003 Oct;21(10):1121-2. doi: 10.1038/nbt883.
8
The YIC factor.
Nat Biotechnol. 2005 Oct;23(10):1187. doi: 10.1038/nbt1005-1187.
9
Chasing biotech, state by state--winners and losers.
Nat Biotechnol. 2005 Feb;23(2):175-9. doi: 10.1038/nbt0205-175.
10
New biotech oasis?
Nat Biotechnol. 2005 Aug;23(8):919. doi: 10.1038/bioent868.
Zotero 插件